Literature DB >> 10479409

Immunohistochemical comparative analysis of transforming growth factor alpha, epidermal growth factor, and epidermal growth factor receptor in normal, hyperplastic and neoplastic human prostates.

P De Miguel1, R Bethencourt, A Ruiz, B Fraile, R Paniagua.   

Abstract

Immunoreaction to TGF-alpha was limited to the basal epithelial cells of focal areas in the normal prostates. In benign prostatic hyperplasia (BPH) the immunostained areas were more widespread and immunolabelling was observed in both basal and columnar (secretory) cells of the epithelium. Some cells in the connective tissue stroma were also stained. In prostatic adenocarcinoma, epithelial immunostaining was even more extensive and intense than in BPH, and some stromal cells were also stained. Epidermal growth factor (EGF) immunostaining was only present in some basal cells in normal prostates. In BPH, this immunoreaction was strong in the basal cells and even stronger in the secretory cells. In prostatic cancer, the intensity of epithelial cell immunoreactivity was intermediate between that of normal prostates and that of BPH specimens. EGF-receptor immunostaining was focal and located in the basal cells in normal prostates. In BPH, labelling was also localized in basal cells but extended to wider areas. Some stromal cells appeared weakly labelled. In the prostatic carcinoma, both basal and columnar cells appeared stained and the number of immunolabelled stromal cells was higher than in BPH. The results presented suggest that, in normal conditions, EGF and TGF-alpha act as autocrine growth factors for the basal cells of the prostatic epithelium. In BPH this action is maintained and, in addition, the columnar cells start to secrete both factors which are bound by the basal cell receptors, giving rise to a paracrine regulation which probably overstimulates basal cell proliferation. In prostatic carcinoma, besides these regulatory mechanisms, the acquisition of EGF-receptors by the secretory cells develops an autocrine regulation which might induce their proliferation. Copyright 1999 Academic Press.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10479409     DOI: 10.1006/cyto.1998.0443

Source DB:  PubMed          Journal:  Cytokine        ISSN: 1043-4666            Impact factor:   3.861


  19 in total

1.  Phosphorylation of both EGFR and ErbB2 is a reliable predictor of prostate cancer cell proliferation in response to EGF.

Authors:  Soha Salama El Sheikh; Jan Domin; Paul Abel; Gordon Stamp; El-Nasir Lalani
Journal:  Neoplasia       Date:  2004 Nov-Dec       Impact factor: 5.715

2.  Epidermal growth factor increases LRF/Pokemon expression in human prostate cancer cells.

Authors:  Himanshu Aggarwal; Anshu Aggarwal; Devendra K Agrawal
Journal:  Exp Mol Pathol       Date:  2011-05-27       Impact factor: 3.362

Review 3.  MicroRNAs that affect prostate cancer: emphasis on prostate cancer in African Americans.

Authors:  J Jones; W Grizzle; H Wang; C Yates
Journal:  Biotech Histochem       Date:  2013-08-01       Impact factor: 1.718

4.  Prostate cancer cell proliferation is strongly reduced by the epidermal growth factor receptor tyrosine kinase inhibitor ZD1839 in vitro on human cell lines and primary cultures.

Authors:  Carlo Vicentini; Claudio Festuccia; Giovanni Luca Gravina; Adriano Angelucci; Angelo Marronaro; Mauro Bologna
Journal:  J Cancer Res Clin Oncol       Date:  2003-03-04       Impact factor: 4.553

5.  Study on the mechanism of epidermal growth factor-induced proliferation of hepatoma cells.

Authors:  Bin-Wen Wu; Yuan Wu; Jia-Long Wang; Ju-Sheng Lin; Shu-Yu Yuan; Ai Li; Wu-Ren Cui
Journal:  World J Gastroenterol       Date:  2003-02       Impact factor: 5.742

6.  Expression of pro-angiogenic growth factors VEGF, EGF and bFGF and their topographical relation to neovascularisation in prostate cancer.

Authors:  Lutz Trojan; Daniel Thomas; Thomas Knoll; Rainer Grobholz; Peter Alken; Maurice Stephan Michel
Journal:  Urol Res       Date:  2004-05

Review 7.  Molecular markers in prostate cancer. Part I: predicting lethality.

Authors:  Sachin Agrawal; William D Dunsmuir
Journal:  Asian J Androl       Date:  2008-12-01       Impact factor: 3.285

Review 8.  Molecular markers in prostate cancer. Part II: potential roles in management.

Authors:  Sachin Agrawal; Krishnaji P Patil; William D Dunsmuir
Journal:  Asian J Androl       Date:  2008-12-01       Impact factor: 3.285

9.  Resveratrol antagonizes EGFR-dependent Erk1/2 activation in human androgen-independent prostate cancer cells with associated isozyme-selective PKC alpha inhibition.

Authors:  Jubilee R Stewart; Catherine A O'Brian
Journal:  Invest New Drugs       Date:  2004-04       Impact factor: 3.850

Review 10.  Androgen-independent prostate cancer: potential role of androgen and ErbB receptor signal transduction crosstalk.

Authors:  Soha Salama El Sheikh; Jan Domin; Paul Abel; Gordon Stamp; El-Nasir Lalani
Journal:  Neoplasia       Date:  2003 Mar-Apr       Impact factor: 5.715

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.